Evidence map›Paper›PMID 41899431›Full record

ArticleCurrent issues in molecular biology2026

Upregulation of miR-4286 and miR-146a-5p in Metastatic Melanoma, Revealed by Multiplex Expression Analysis.

Iliyan Pochileev, Albena Fakirova, Desislava Tashkova, Aleksandra Gerdgikova, Nevena Ilieva, Denitsa Serteva, Gergana Shalamanova, Hristo Ivanov, Aleksandar Linev, Ivanka Dimova

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Iliyan PochileevDepartment of Medical Genetics, Medical University of Sofia, 1431 Sofia, Bulgaria.ORCID 0009-0002-8445-2583
Albena FakirovaClinic of General and Clinical Pathology, Military Medical Academy, 1606 Sofia, Bulgaria.
Desislava TashkovaDepartment of General and Clinical Pathology, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria.ORCID 0000-0002-1158-1379
Aleksandra GerdgikovaDepartment of General and Clinical Pathology, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria.ORCID 0009-0004-3315-0897
Nevena IlievaDepartment of General and Clinical Pathology, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria.
Denitsa SertevaDepartment of General and Clinical Pathology, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria.
Gergana ShalamanovaDepartment of Oncodermatology, Oncology Center Plovdiv, 4000 Plovdiv, Bulgaria.
Hristo IvanovDepartment of Medical Genetics, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria.ORCID 0000-0002-7912-3673
Aleksandar LinevDepartment of Medical Genetics, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria.
Ivanka DimovaDepartment of Medical Genetics, Medical University of Sofia, 1431 Sofia, Bulgaria.

Funding

European Union through the NextGenerationEU instrument under the Bulgarian National Recovery and Resilience Plan BG-RRP-2.004-0004-C01
6 · The paper itself

Abstract

backgroundMetastatic melanoma is an extremely aggressive malignancy with limited therapeutic options, despite advances in targeted and immunotherapy. MicroRNAs are key post-transcriptional regulators of gene expression and play a critical role in tumor adaptation, invasion, and metastasis. The aim of our study was to identify dysregulated miRNAs which may serve as novel biomarkers and therapeutic targets. MATERIALS AND

methodsThe study was conducted on FFPE samples from metastatic melanoma (n = 15), compared to healthy skin tissue (n = 6). BRAF V600E/Ec mutation status was established by Real-Time qPCR. Expression miRNA analysis was performed, using digital counting of 827 miRNAs on the NanoString platform, with data normalization and fold change calculations.

resultsFollowing normalization and quality control metrics, 58 differentially expressed miRNAs were identified in BRAFwt melanoma samples: 6 overexpressed and 52 inderexpressed miRNAs. In BRAFmut melanoma, 37 microRNAs were differentially expressed: 11 overexpressed and 26 underexpressed. Four miRNAs showed elevated expression in both melanoma groups. Among them, miR-146a-5p and miR-4286 demonstrated the highest elevation, especially in BRAFmut tumors. We focused further on their targeted genes.

conclusionThis study demonstrates significant alterations in the miRNA expression profile in metastatic melanoma and highlights the potential of miR-146a-5p and miR-4286 as key regulators of tumor biology.

Indexed as

BRAFmetastatic melanomamicroRNA biomarkersmiR-146a-5pmiR-4286miRNANanoString technology

Identifiers

PMID41899431
PMCPMC13025385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.